EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies

Yuzhu Chen, Fei Qi iD, Chenhao Sun, Peng Jiang, Xiangyu Xue, Xiaomei Yang, Xiaomi Li, Xin He, Yishuo Wang, Tongmei Zhang iD

Therapeutic Advances in Medical Oncology · 2025-01 · 17

DOI: 10.1177/17588359241312501 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 08.01.2025. Verfasst von Yuzhu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, Chin…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapyneoadjuvant therapynon-small-cell lung cancertumor microenvironment

Autor:innen und Institutionen

  • Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Department of Biochemistry and Molecular Biology, Heilongjiang Provincial Science and Technology Innovation Team in Higher Education Institutes for Infection and Immunity, Harbin Medical University, Harbin, China.
  • Beijing Key Laboratory for Tumor Invasion and Metastasis, Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing, China.

ORCID-Profile: Fei Qi, Tongmei Zhang

Förderung

  • Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes

Zitieren

APA

Chen, Y., Qi, F., Sun, C., Jiang, P., Xue, X., Yang, X., Li, X., He, X., Wang, Y., & Zhang, T. (2025). Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359241312501

Vancouver

Chen Y, Qi F, Sun C, Jiang P, Xue X, Yang X, et al. Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359241312501

BibTeX
@article{Chen2025,
  author = {Chen, Yuzhu and Qi, Fei and Sun, Chenhao and Jiang, Peng and Xue, Xiangyu and Yang, Xiaomei and Li, Xiaomi and He, Xin and Wang, Yishuo and Zhang, Tongmei},
  title = {Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359241312501}
}
Kostenlos starten →